1What ICH Q2(R2) covers.
ICH Q2(R2), Validation of Analytical Procedures, is a complete revision of Q2(R1), adopted at Step 4 on 1 November 2023 and corrected on 30 November 2023 and 4 April 2025.¹ Its objective is “to demonstrate that the analytical procedure is fit for the intended purpose”.¹ It applies to procedures used for release and stability testing of commercial drug substances and products. It can be applied to other procedures in the control strategy following a risk-based approach, and its principles can be applied “in a phase-appropriate manner” during clinical development.¹
Q2(R2) is guidance. The EMA lists it as legally effective in the EU from 14 June 2024,² and FDA published Q2(R2) and Q14 as final guidances in March 2024.³ The duty to validate comes from GMP. In the US, 21 CFR 211.165(e) requires that “the accuracy, sensitivity, specificity, and reproducibility of test methods employed by the firm shall be established and documented”.⁴ In the EU, Chapter 6 of the GMP guide says “Testing methods should be validated.”⁵
2What a validation study must show.
Before the study, the applicant writes a validation protocol stating the procedure’s intended purpose, the performance characteristics to be validated and their acceptance criteria. The results are summarised in a validation report.¹ The study design should reflect the number of replicates used in routine analysis to generate a reportable result.¹
Which characteristics apply depends on the use. An identity test needs specificity. A quantitative impurity test needs specificity, response, a quantitation limit, accuracy and precision. A limit test needs specificity and a detection limit. An assay needs specificity, response, accuracy and precision.¹
| Characteristic | What Q2(R2) recommends |
|---|---|
| Specificity or selectivity | Show that impurities, degradation products or matrix don’t affect the result, compare with an orthogonal procedure, or justify it from the technology itself. |
| Response | For a linear response, at least five concentrations across the range, with the correlation coefficient, y-intercept, slope and residuals. |
| Lower range limits | Detection limit (DL) and quantitation limit (QL) by visual evaluation, signal-to-noise (3:1 for the DL, at least 10:1 for the QL) or the standard deviation of the response and the slope. An impurity test’s QL should be at or below the reporting threshold. |
| Accuracy | Across the reportable range, for example 3 concentrations with 3 replicates each, reported as mean recovery or difference from the true value, with a confidence interval. |
| Repeatability | At least 9 determinations across the range, or at least 6 at 100% of the test concentration. |
| Intermediate precision | The effects of different days, environmental conditions, analysts and equipment, as relevant. |
| Reproducibility | An inter-laboratory trial, usually not required for submission but considered for pharmacopoeial standardisation or use at several sites. |
Accuracy and precision can instead be evaluated together against a combined criterion, using a prediction, tolerance or confidence interval.¹ The reportable range is typically derived from the specification and should include the upper and lower specification or reporting limits. Table 2 of the guideline gives examples: 80% to 120% of declared content for an assay, and from the reporting threshold to 120% of the acceptance criterion for an impurity.¹
3Robustness and stability-indicating procedures.
Robustness is “typically evaluated as part of development prior to the execution of the analytical procedure validation study”.¹ It shows the procedure’s reliability under deliberate variations in its parameters and, where appropriate, the stability of sample preparations and reagents for the duration of the procedure. The evaluation can be submitted with development data or made available on request.¹ If robustness was evaluated during development, it does not need to be repeated during validation.⁶
A validated quantitative procedure that can detect changes in relevant quality attributes during storage is stability-
4How ICH Q14 relates to Q2(R2).
ICH Q14, Analytical Procedure Development, was adopted on the same day and “complements ICH Q2”.⁶ Q14 covers how a procedure is developed and changed; Q2(R2) covers how it is validated. Data from development, such as robustness results from a designed experiment, can form part of the validation data, and validation of an established platform procedure used for a new purpose can be abbreviated if scientifically justified.¹⁶
| ICH Q2(R2) | ICH Q14 | |
|---|---|---|
| Subject | Validation of analytical procedures | Development and lifecycle management of analytical procedures |
| Main records | Validation protocol and validation report | Analytical target profile where used, risk assessment, analytical procedure control strategy |
| Robustness | Points to development (section 3.4) | Evaluated during development (section 5.1) |
| Changes | Partial or full revalidation of the characteristics a change affects (section 2.2) | Bridging studies scaled to risk and knowledge, with established conditions and reporting categories (chapters 6 and 7) |
Q14 describes two approaches. The minimal approach identifies the attributes to test, selects the technology, evaluates specificity, accuracy, precision over the reportable range and robustness, and documents the procedure with its control strategy. The enhanced approach adds an analytical target profile (ATP), risk assessment, uni- or multivariate experiments, and set-points or ranges such as proven acceptable ranges (PARs) and method operable design regions (MODRs).⁶ An ATP describes the intended purpose, the attributes to be measured and the performance criteria; formal documentation and submission of one is optional.⁶
The analytical procedure control strategy, which includes the system suitability test, “should be defined before validation (ICH Q2) and should be confirmed after validation has been finalised”.⁶ Approved ranges also pay off later: “Moving within an approved PAR or MODR does not require regulatory notification.”⁶
5When a validated procedure must be revalidated.
Changes during a procedure’s lifecycle may require partial or full revalidation, and the extent depends on the performance characteristics the change affects.¹ Transfer to another laboratory calls for partial or full revalidation, comparative analysis of representative samples, or both, or a justification for doing neither; co-validation across sites can also satisfy transfer.¹ FDA’s 2015 guidance on analytical procedures, which still names Q2(R1) as its primary reference, adds that method performance should be trended at regular intervals. A procedure that meets system suitability only “with repeated adjustments to the operating conditions” should be re-evaluated, revalidated or amended.⁷
6How it runs in Seal.
In Seal, the analytical method lifecycle keeps a method’s intended use, procedure versions, development and validation studies, transfer work and routine performance connected. A validation study is configured with its performance characteristics, preparations, replicates and acceptance criteria before execution, and keeps source files, calculations, invalid runs and protocol exceptions with the resulting assessment. Analytical development runs forced degradation and robustness studies against versioned protocols, keeping the conditions that failed.
Neil, Seal’s AI agent, can assemble a method validation report that traces each claim to its protocol criterion and source experiment, with missing evidence left open rather than covered by a general conclusion. The method owner verifies the calculations and assesses exceptions, and QA approves the report.
References
- 1ICH Q2(R2) Validation of Analytical Procedures, ICH, adopted 1 November 2023, error corrections 30 November 2023 and 4 April 2025. https:/
/ database. ich. org/ sites/ default/ files/ ICH_ Q2%28R2%29_ Guideline_ 2023_ 1130_ ErrorCorrection_ 2025. pdf (read 6 November 2026) - 2ICH Q2(R2) Validation of analytical procedures, Scientific guideline, European Medicines Agency, last updated 20 February 2026. https:/
/ www. ema. europa. eu/ en/ ich- q2r2- validation- analytical- procedures- scientific- guideline (read 6 November 2026) - 3Q14 Analytical Procedure Development, Guidance for Industry, FDA, March 2024. https:/
/ www. fda. gov/ regulatory- information/ search- fda- guidance- documents/ q14- analytical- procedure- development (read 6 November 2026) - 421 CFR 211.165, Testing and release for distribution, eCFR. https:/
/ www. ecfr. gov/ current/ title- 21/ section- 211. 165 (read 6 November 2026) - 5EudraLex Volume 4, Part I, Chapter 6: Quality Control, European Commission, in operation since 1 October 2014. https:/
/ health. ec. europa. eu/ document/ download/ c74c8720- 27bf- 4252- 808f- d65a206a90bb_ en?filename=2014- 11_ vol4_ chapter_ 6. pdf (read 6 November 2026) - 6ICH Q14 Analytical Procedure Development, ICH, adopted 1 November 2023. https:/
/ database. ich. org/ sites/ default/ files/ ICH_ Q14_ Guideline_ 2023_ 1116. pdf (read 6 November 2026) - 7Analytical Procedures and Methods Validation for Drugs and Biologics, Guidance for Industry, FDA, July 2015. https:/
/ www. fda. gov/ media/ 87801/ download (read 6 November 2026)
AQuestions and answers
What is a stability-indicating method?
A validated quantitative procedure that can detect changes in a product’s relevant quality attributes during storage. Its specificity is shown with samples that contain the relevant degradation products: spiked samples, samples exposed to physical and chemical stress, and product that is aged or has been stored under stressed conditions.
Is forced degradation part of method validation?
Forced degradation studies are development work, but they supply the stressed samples that show a stability-
Do we have to write an analytical target profile?
No. ICH Q14 says formal documentation and submission of an ATP is optional, whichever development approach you take. It can still help communication with regulators, and it can serve as the basis for managing later changes to the procedure.
Does robustness have to be repeated during validation?
Not if it was evaluated during development. Both guidelines place robustness in development, and Q14 says it need not be repeated during validation. The outcome should be documented and reflected in the procedure’s control strategy.
Do compendial methods need full validation?
In the US, an unmodified method from the USP or another recognised reference needs only a statement of the method and its reference, but its suitability must be verified under actual conditions of use. In the EU, a laboratory that did not perform the original validation should verify that the method is appropriate.
Does Q2(R2) apply to methods used in clinical trials?
Its scope is release and stability testing of commercial products. Its scientific principles can be applied in a phase-appropriate manner to procedures used during clinical development.